Estimating Cost Drivers for First-in-Human Studies
When planning a first-in-human study, understanding and managing costs is one of the most critical steps in early development. These studies mark the first time a new drug or medical device is tested in humans, and while costs can vary widely, several consistent drivers determine the overall budget.
Major expenses typically include participant recruitment and retention, regulatory and ethics approvals, site operations, and study monitoring. Design complexity—such as adaptive dose-escalation methods—can also significantly impact total costs. On average, regulatory and compliance activities can consume up to a third of the total study budget, underscoring the importance of meticulous planning and documentation.
Innovative approaches like adaptive trial designs, real-world data integration, and strategic site selection can help reduce costs while maintaining scientific rigor and patient safety. Conducting trials in regions with efficient regulatory processes or leveraging experienced local partners can also enhance cost efficiency.
Ultimately, a successful first-in-human study requires more than funding—it demands precise planning, clear communication between stakeholders, and proactive risk management. By understanding the primary cost drivers and optimizing resources early, sponsors can control budgets, maintain quality, and bring innovative therapies or devices closer to improving patient lives.
Comments
Post a Comment